Gene signature might identify patients at risk of CAR T-associated neurotoxicityJune 19, 2018Leukemia, Myelodysplasia, TransplantationALL
FDA places SB-generated CAR T-cell therapy on clinical holdJune 19, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
Quizartinib can prolong OS in rel/ref, FLT3-ITD AMLJune 18, 2018Leukemia, Myelodysplasia, TransplantationAML
Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomabJune 17, 2018Leukemia, Myelodysplasia, TransplantationALL
Ivosidenib active in R/R IDH1-mutated AML patientsJune 14, 2018Leukemia, Myelodysplasia, TransplantationAML
Dasatinib outcomes similar to imatinib in pediatric Ph+ ALLJune 9, 2018Leukemia, Myelodysplasia, TransplantationPediatricsTransplantationALL
Two agents could take AML therapy in new directionsJune 7, 2018Leukemia, Myelodysplasia, TransplantationAML
FDA approves first biosimilar pegfilgrastimJune 5, 2018AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacy
Over 1100 new meds, vaccines being developed to treat cancerJune 4, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacy
VF incidence increases significantly in kids after ALL treatmentMay 31, 2018Leukemia, Myelodysplasia, TransplantationPediatricsALL
FDA grants priority review to gilteritinib for R/R AMLMay 30, 2018Leukemia, Myelodysplasia, TransplantationPharmacyAML
Early infection could prevent ALL, doc saysMay 22, 2018Leukemia, Myelodysplasia, TransplantationPediatricsALL
Older, cheaper drug formulation to remain availableMay 21, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaAggressive Lymphomas
